KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called KAZ954 alone and with other drugs to find the safest and most effective dose for patients with advanced cancer. The goal is to see if these treatments can help patients who haven't responded to standard therapies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
The dose escalation part estimated the MTD and/or RD and tested different dosing schedules.
Dose Expansion
Planned to use the MTD/RDE determined in the dose escalation part to assess the activity, safety, and tolerability of the investigational products.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KAZ954
- NIR178
- NZV930
- PDR001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD